CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?

Independent drug launches are highly unpredictable, but CRISPR Therapeutics can lean on its collaboration partner, Vertex Pharmaceuticals (VRTX 0.40%). Vertex successfully markets the first and only FDA-approved treatments that address the underlying cause of cystic fibrosis, another rare disease. With product sales that grew past $11 billion last year, it's clear Vertex knows a thing or two about selling rare disease drugs. CRISPR Therapeutics is still losing money, but it also finished March with$1.9 bil ...